This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Allergic reactions
  • /
  • Validation of the MASK-rhinitis visual analogue sc...

Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

Read time: 1 mins
Published:1st Dec 2017
Author: <span style="font-size:11.0pt;line-height:107%; font-family:&quot;Nexa Light&quot;;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;mso-fareast-language: EN-US;mso-bidi-language:AR-SA">Ciammi D, Biaz N, Tanno LK, Demoly P, Arnavielhe S, Murray R, et al. </span>
Availability: Pay for access, or by subscription
Ref.:Clin Exp Allergy. 2017 Dec;47(12):1526-1533.


Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitispatients.


The aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control.


Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity, and acceptability of the MASK-Rhinitis VAS.


Between 1 August 2015 and 31 July 2016, the app was used 14 612 times in 15 countries. A total of 1225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test > 0.84, test-retest > 0.7), reliability (>0.9), and acceptability. In addition, the tool had a good sensitivity when users (n = 521) answered the VAS twice in less than 3 hours.


The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level.


Read abstract on library site

Access full article